CVS Health Corporation · NYSE (us_market)
Healthcare · Healthcare Plans · United States
CVS Health Corporation provides health solutions in the United States. The company operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services, including medical, pharmacy, dental and behavioral health plans, medical management capabilities, Medicare Advantage and Medicare Supplement plans, PDPS and Medicaid health care management services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. The Health Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, specialty and mail order pharmacy, clinical, disease management, medical spend management services, pharmacy and other administrative services. It serves employers, insurance companies, unions, government employee groups, health plans, PDPS, Medicaid managed care plans, CMS, plans offered on public health insurance, and other sponsors of health benefit plans. The Pharmacy & Consumer Wellness segment sells prescription and over-the-counter drugs, consumer health and beauty products, personal care products, and other general merchandise products. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. It operates online retail pharmacy websites, retail specialty pharmacy stores, compounding pharmacies and branches for infusion and enteral nutrition services. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-26$83.87 RISE2026-03-27$70.08 PEAK2026-05-13$98.11 107d | -16.4% 60d | Missed | Missed | — | — | +40.0% 47d | Missed |
DROP2025-04-09$70.18 RISE2025-07-24$58.75 PEAK2025-10-17$82.52 191d | -16.3% 106d | Missed | Missed | — | — | +40.5% 85d | Missed |
DROP2024-10-14$67.46 RISE2024-12-19$43.78 PEAK2025-03-20$68.64 157d | -35.1% 66d | Missed | Missed | — | — | +56.8% 91d | Missed |
DROP2024-04-03$74.60 RISE2024-08-12$55.81 PEAK2024-10-14$67.46 194d | -25.2% 131d | Missed | Missed | — | — | +20.9% 63d | Missed |
DROP2024-03-28$79.76 RISE2024-05-28$53.63 PEAK2024-07-30$63.18 124d | -32.8% 61d | Missed | Missed | — | — | +17.8% 63d | Missed |
DROP2022-08-16$106.43 RISE2022-10-12$87.84 PEAK2022-12-12$103.79 118d | -17.5% 57d | Missed | Missed | — | — | +18.2% 61d | Missed |
DROP2022-02-08$110.83 RISE2022-06-17$88.66 PEAK2022-08-16$106.43 189d | -20.0% 129d | Missed | Missed | — | — | +20.0% 60d | Missed |
DROP2020-06-08$70.62 RISE2020-09-24$56.71 PEAK2020-12-04$74.50 179d | -19.7% 108d | Missed | Missed | — | — | +31.4% 71d | Missed |
DROP2020-01-16$76.05 RISE2020-03-16$52.30 PEAK2020-06-08$70.62 144d | -31.2% 60d | Missed | Missed | — | — | +35.0% 84d | Missed |
Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
CVS restores broader Zepbound coverage after price cuts, putting Wegovy and Zepbound on equal footing.
CVS Health (NYSE:CVS) has launched Aetna Mental Health On Demand to widen access to virtual behavioral health services. The company is expanding its pharmacy benefits with updated GLP-1 formulary options for weight loss medications. CVS Health has broadened its AI-focused collaboration with Salesforce to support members and providers through more tailored digital tools. For investors watching NYSE:CVS, these moves sit at the intersection of managed care, retail pharmacy, and digital health...
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the afternoon session after CVS restored Zepbound as a co-preferred option and simultaneously added Lilly's new oral obesity pill Foundayo, making Eli Lilly's full obesity medication portfolio accessible to all three of America's largest pharmacy benefit managers for the first time.
CVS Health Corporation (NYSE:CVS) is one of the 12 Strong Buy Stocks to Buy and Hold for the Next 5 Years. On May 21, 2026, Glenview Capital said CVS Health Corporation (NYSE:CVS) remains one of its three largest positions after a partial rebalance. Glenview said CVS shares have generated a total return of 80% since […]
The change could improve patient access and support future sales growth.
The move gives patients broader access to Lilly's obesity drugs and strengthens competition with Novo Nordisk.
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.
Investors shouldn't lose sleep over the possibility that the dividend is in danger.
Today, May 28, 2026, investors piled into Snowflake after its Amazon pact and earnings beat, even as the Dow barely budged.
CEO Ariel Katz argues that while AI can replicate workflow SaaS, it can't copy H1’s unique doctor data.
CVS Health will reinstate coverage of Eli Lilly's weight-loss injectable Zepbound and begin coverage of the anti-obesity pill Foundayo.
CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug business.
Eva Boratto, who spent more than a decade at CVS in a variety of finance roles, will join the drug distributor later this summer, Cencora announced Wednesday.
The law, which would prohibit PBM conglomerates from owning or operating pharmacies, illegally boots out-of-state companies from Tennessee’s pharmacy market, CVS argued in a suit filed Friday.
The S&P 500 Index ($SPX ) (SPY ) on Tuesday closed up +0.61%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +1.76%. June E-mini S&P futures (ESM26 ) rose +0.61%, and June E-mini Nasdaq futures...
The S&P 500 Index ($SPX ) (SPY ) today is up +0.81%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is down -0.10%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.74%. June E-mini S&P futures (ESM26 ) are up +0.77%, and June E-mini Nasdaq futures...
Hartford HealthCare becomes one of the first clinically integrated networks in the region to include MinuteClinic as an in-network primary care option HARTFORD, CT / ACCESS Newswire / May 26, 2026 /Originally published on CVS Health Company News MinuteClinic®, ...
Aetna®, a CVS Health® company (NYSE: CVS), today announced the launch of the second generation Aetna Claims Assist Manager (CAM), an AI-powered agentic claims advisor platform designed to streamline claims processing and improve payment accuracy.
CVS Health Corporation (NYSE:CVS) is one of the best medical stocks to invest in according to billionaires. Morgan Stanley lifted the price target on CVS Health Corporation (NYSE:CVS) to $106 from $93 on May 14, maintaining an Overweight rating on the shares. CVS Health Corporation (NYSE:CVS) also received a rating update from Bernstein on May 13, […]
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| CVS | +10.83% | +11.41% | +14.64% | +42.07% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +7.86% | +17.13% | +18.09% | +29.38% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 59.32M | $4.26B | 0.15% | Trimmed-1.4% | 2026-03-31 |
| FidelityFMR | fundamental | 31.20M | $2.24B | 0.12% | Trimmed-23.9% | 2026-03-31 |
| Wellington | fundamental | 22.57M | $1.62B | 0.30% | Added+21.6% | 2026-03-31 |
| CapResearch | fundamental | 20.01M | $1.44B | 0.22% | Added+66.2% | 2026-03-31 |
| DEShaw | quant | 1.62M | $116.17M | 0.07% | Added+50.5% | 2026-03-31 |
| Bridgewater | macro | 618.4K | $44.42M | 0.20% | Trimmed-40.4% | 2026-03-31 |
| RenTech | quant | 263.2K | $18.90M | 0.03% | New | 2026-03-31 |
| TRowePrice | fundamental | 23.78M | $1.71M | 0.20% | Added+44.6% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-22 | AGUIRRE FERNANDO | Director | D Disposition (other) | 1,563 | $93.50 | −$146.1K |
| 2026-05-22 | AGUIRRE FERNANDO | Director | D Disposition (other) | 30,437 | $93.78 | −$2.85M |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale(deriv) | 378,000 | $93.31 | −$35.27M |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 370,462 | $93.45 | −$34.62M |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 800 | $96.28 | −$77.0K |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 66,881 | $95.67 | −$6.40M |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 152,691 | $94.81 | −$14.48M |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 797,628 | $93.48 | −$74.56M |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 151 | $95.18 | −$14.4K |
| 2026-05-21 | ROBBINS LARRY | Director | S Open-market sale | 1,983,387 | $94.45 | −$187.33M |
| 2026-05-15 | ROBBINS LARRY | Director | A Grant / award(deriv) | 1,930 | $97.15 | +$187.5K |
| 2026-05-15 | Shulman Douglas H. | Director | A Grant / award(deriv) | 1,448 | $97.15 | +$140.6K |
| 2026-05-15 | BROWN C DAVID II | Director | A Grant / award | 1,544 | $97.15 | +$150.0K |
| 2026-05-15 | Finucane Anne A. | Director | A Grant / award(deriv) | 1,544 | $97.15 | +$150.0K |
| 2026-05-15 | DECOUDREAUX ALECIA A | Director | A Grant / award(deriv) | 1,448 | $97.15 | +$140.6K |
| 2026-05-15 | SANSONE GUY P | Director | A Grant / award | 1,447 | $97.15 | +$140.6K |
| 2026-05-15 | Norwalk Leslie V | Director | A Grant / award | 1,447 | $97.15 | +$140.6K |
| 2026-05-15 | KIRBY J SCOTT | Director | A Grant / award | 1,447 | $97.15 | +$140.6K |
| 2026-05-15 | Balser Jeffrey R. | Director | A Grant / award | 2,058 | $97.15 | +$199.9K |
| 2026-05-15 | AGUIRRE FERNANDO | Director | A Grant / award | 1,563 | $97.15 | +$151.8K |
| 2026-05-15 | Mahoney Michael F | Director | A Grant / award(deriv) | 1,737 | $97.15 | +$168.7K |
| 2026-05-15 | Gallina John E | Director | A Grant / award(deriv) | 1,448 | $97.15 | +$140.6K |
| 2026-05-11 | Mandadi Tilak | EVP, Chief Exp & Tech Officer | S Open-market sale | 69,551 | $89.58 | −$6.23M |
| 2026-04-02 | CAPOZZI HEIDI B | EVP and Chief People Officer | A Grant / award(deriv) | 64,670 | $71.82 | +$4.64M |
| 2026-04-02 | CAPOZZI HEIDI B | EVP and Chief People Officer | F Tax withholding | 1,334 | $72.49 | −$96.7K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-07-30upcoming | 1.82 | — | — |
| 2026-05-06 | 2.21 | 2.57 | +16.48% |
| 2026-02-10 | 1.00 | 1.09 | +9.38% |
| 2025-10-29 | 1.36 | 1.60 | +17.93% |
| 2025-07-31 | 1.46 | 1.81 | +23.85% |
| 2025-05-01 | 1.67 | 2.25 | +34.49% |
| 2025-02-12 | 0.92 | 1.19 | +29.56% |
| 2024-11-06 | 1.31 | 0.07 | -94.66% |
| 2024-08-07 | 1.73 | 1.83 | +5.95% |
| 2024-05-01 | 1.70 | 1.31 | -22.79% |
| 2024-02-07 | 1.99 | 2.12 | +6.59% |
| 2023-11-01 | 2.13 | 2.21 | +3.72% |
| 2023-08-02 | 2.12 | 2.21 | +4.23% |
| 2023-05-03 | 2.09 | 2.20 | +5.16% |
| 2023-02-08 | 1.93 | 1.99 | +3.14% |
| 2022-11-02 | 1.99 | 2.15 | +7.94% |